FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · adults and children with cystic fibrosis
1 finding from 1 review
Other measures of lung function: mean change from baseline in FEV1 AUC0-4h (% predicted) after tiotropium 5.0 µg · adults and children with cystic fibrosis
1 finding from 1 review
Change in baseline trough FEV1 · adults and children with cystic fibrosis
1 finding from 1 review
Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other measures of lung function · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lung function: FEV1 mL (change from baseline) · adults and children with cystic fibrosis
1 finding from 1 review
Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis
LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis
LAMAs showed no clear difference in pulmonary exacerbations: participants reporting ≥1 pulmonary… compared with placebo (moderate certainty).
1 finding from 1 review